IL-6 induces the development of HCC through activation of the JAK–STAT3 pathway, and IL-1β enhances the survival of DNA damaged cells in HCC through activation of the phosphoinositide 3-kinase- (PI3K-) MDM2 pathway. Here, STAT3 is linked to hepatocellular carcinoma.